clinical trial · NCT05774756
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Hypothalamic ObesitySetmelanotidePlacebo
brief summary
The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for 52 weeks on a therapeutic regimen. A separate sub-study in patients with congenital HO is detailed under NCT06760546.
started
Apr 26, 2023
primary completion
Mar 18, 2025
completion
Apr 16, 2027
last updated
Jul 2, 2025
official title
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol